Disparity in market prices for hepatitis C virus direct-acting drugs

The Lancet Global Health

Volumn 3, Issue 11, 2015, Pages e676-e677

  Andrieux Meyer, Isabelle ^a   Cohn, Jennifer ^a   de Araújo, Evaldo S Affonso ^b   Hamid, Saeed S ^c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; DIRECT ACTING ANTIVIRAL DRUG; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG;

DECISION MAKING; DRUG COST; DRUG MARKETING; HEALTH CARE COST; HEPATITIS C VIRUS; HUMAN; INCOME; LETTER; PRIORITY JOURNAL; STRUCTURED QUESTIONNAIRE; COMMERCIAL PHENOMENA; ECONOMICS; HEALTH CARE DISPARITY; HEPATITIS C;

ANTIVIRAL AGENTS; COMMERCE; DRUG COSTS; HEALTHCARE DISPARITIES; HEPATITIS C; HUMANS;

EID: 84944252126     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(15)00156-4     Document Type: Letter

References (5)

1. Hill A, Khoo S, Fortunak J, Simmons B, Ford N Minimum costs for producing hepatitis C direct acting antivirals, for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014, 58:928-936.
2. Human Development Report 2014, UNDP, United Nations Development Programme, New York.
3. MSF analysis of Gilead's voluntary license agreement Médecins Sans Frontières, (accessed June 20, 2015). http://www.msfaccess.org/content/msf-analysis-gilead-hepatitis-c-license-march-2015.
4. Strategies to secure access to generic hepatitis C medicines. MSF access briefing document Médecins Sans Frontières, (accessed June 20, 2015). http://www.msfaccess.org/content/strategies-secure-access-generic-hepatitis-c-medicines.
5. EASL recommendations on treatment of hepatitis C in 2015. J Hepatol 2015, 63:199-236. European Association for the Study of the Liver.